Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion and placebo
- PMID: 16102908
- DOI: 10.1016/j.drugalcdep.2005.06.012
Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion and placebo
Abstract
The purpose of this double-blind, three-arm, 12-week trial was to compare the efficacy of sustained-release methylphenidate or sustained-release bupropion to placebo in treating adult attention deficit hyperactivity disorder (ADHD) symptoms. The randomized sample consisted of 98 methadone-maintained patients who were pre-dominantly male (57%) and 40% Caucasian, 40% Hispanic and 20% African American. All participants met DSM-IV criteria for adult ADHD, with 53% meeting DSM-IV criteria for cocaine dependence/abuse. In addition to medication and treatment as usual at a methadone program, individuals received weekly individual cognitive behavioral treatment. Other than current employment status, there were no significant demographic differences across the three treatment groups. Seventy percent completed the 12-week trial. There were no differences in retention rate based on treatment group. A reduction in ADHD symptoms using the adult ADHD rating scale was observed in all three groups, but there were no significant differences in outcome between treatments. The placebo response rate was high, with 46% of the placebo group self-reporting substantial improvement in their ADHD symptoms (>30% reduction in adult ADHD rating scale). Using other ADHD outcome measures, the placebo response and medication response rates were substantially lower. There was no evidence of misuse of medication or worsening of cocaine use among those randomized to methylphenidate. Taken together, sustained-release methylphenidate or sustained-release bupropion did not provide a clear advantage over placebo in reducing ADHD symptoms or additional cocaine use in methadone-maintained patients.
Similar articles
-
Treatment of cocaine dependent treatment seekers with adult ADHD: double-blind comparison of methylphenidate and placebo.Drug Alcohol Depend. 2007 Feb 23;87(1):20-9. doi: 10.1016/j.drugalcdep.2006.07.004. Epub 2006 Aug 22. Drug Alcohol Depend. 2007. PMID: 16930863 Clinical Trial.
-
Sustained release methylphenidate for the treatment of ADHD in amphetamine abusers: a pilot study.Drug Alcohol Depend. 2010 Apr 1;108(1-2):130-3. doi: 10.1016/j.drugalcdep.2009.11.006. Epub 2009 Dec 16. Drug Alcohol Depend. 2010. PMID: 20015599 Clinical Trial.
-
Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.Clin Ther. 2006 Feb;28(2):266-79. doi: 10.1016/j.clinthera.2006.02.011. Clin Ther. 2006. PMID: 16678648 Clinical Trial.
-
Attention-deficit-hyperactivity disorder: an update.Pharmacotherapy. 2009 Jun;29(6):656-79. doi: 10.1592/phco.29.6.656. Pharmacotherapy. 2009. PMID: 19476419 Review.
-
Pharmacotherapy of attention-deficit/hyperactivity disorder in adults.J Clin Psychiatry. 1998;59 Suppl 7:76-9. J Clin Psychiatry. 1998. PMID: 9680056 Review.
Cited by
-
Clinical potential of methylphenidate in the treatment of cocaine addiction: a review of the current evidence.Subst Abuse Rehabil. 2015 Jun 17;6:61-74. doi: 10.2147/SAR.S50807. eCollection 2015. Subst Abuse Rehabil. 2015. PMID: 26124696 Free PMC article. Review.
-
How treatment improvement in ADHD and cocaine dependence are related to one another: A secondary analysis.Drug Alcohol Depend. 2018 Jul 1;188:135-140. doi: 10.1016/j.drugalcdep.2018.03.043. Epub 2018 May 1. Drug Alcohol Depend. 2018. PMID: 29775957 Free PMC article. Clinical Trial.
-
Treatment of adult ADHD: is current knowledge useful to clinicians?Neuropsychiatr Dis Treat. 2008 Feb;4(1):177-86. doi: 10.2147/ndt.s1223. Neuropsychiatr Dis Treat. 2008. PMID: 18728815 Free PMC article.
-
A review of OROS methylphenidate (Concerta(®)) in the treatment of attention-deficit/hyperactivity disorder.CNS Drugs. 2014 Nov;28(11):1005-33. doi: 10.1007/s40263-014-0175-1. CNS Drugs. 2014. PMID: 25120227 Review.
-
A systematic review of randomized controlled trials of bupropion versus methylphenidate in the treatment of attention-deficit/hyperactivity disorder.Neuropsychiatr Dis Treat. 2014 Aug 1;10:1439-49. doi: 10.2147/NDT.S62714. eCollection 2014. Neuropsychiatr Dis Treat. 2014. PMID: 25120365 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous